Ricardo Munoz-Garcia
LO, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Immune Effector Cell-associated Hemophagocytic Syndrome (IEC-HS) as a late immune-mediated toxicity after CAR-T therapy in Diffuse Large B-Cell Lymphoma (DLBCL): a case report.
Journal: Annals of hematology
Published: March 05, 2026
Predictive value of natural killer (NK) cells in bone marrow for relapse in diffuse large B cell lymphoma: integrating antibody-dependent cell-mediated cytotoxicity (ADCC)-based immunotherapy.
Journal: Cancer immunology, immunotherapy : CII
Published: August 01, 2025
SOX4 in chronic lymphocytic leukaemia: the forgotten transcription factor.
Journal: Blood research
Published: March 27, 2025
Serology-based therapeutic strategy in SARS-CoV-2-infected patients.
Journal: International immunopharmacology
Published: August 18, 2021
Peripheral blood natural killer cell depletion is associated with severe pneumonia in coronavirus disease-2019 (COVID-19).
Journal: Irish journal of medical science
Published: June 08, 2021
Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study).
Journal: Clinical lymphoma, myeloma & leukemia
Published: May 21, 2021
A new case of Bicêtre hemoglobin in an adult male: clinical observations over a period of four years.
Journal: Annals of hematology
Published: March 11, 2021
Battle of Thermopylae: 300 Spartans (natural killer cells plus obinutuzumab) versus the immortal warriors (chronic lymphocytic leukemia cells) of Xerxes' army.
Journal: Future science OA
Published: December 13, 2019
Maintenance therapy with ex vivo expanded lymphokine-activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progression.
Journal: British journal of haematology
Published: October 07, 2019
Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella study.
Journal: British journal of haematology
Published: April 05, 2019
Full donor chimerism without graft-versus-host disease: the key factor for maximum benefit of pre-emptive donor lymphocyte infusions (pDLI).
Journal: Bone marrow transplantation
Published: March 06, 2019
GALLIUM trial: the tortoise (rituximab) and the hare (obinutuzumab) race.
Journal: Future science OA
Published: December 14, 2018
Last Updated: 09/26/2026